The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14).
 
Muhammad Furqan
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; BeiGene; BeiGene; Jazz Pharmaceuticals; Mirati Therapeutics; Novartis; Omega Therapeutics
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Biothera (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jacobus Pharmaceutical Company (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst)
 
Siddharth Karanth
Research Funding - RTI Health Solutions (Inst)
 
Ravi K. Goyal
Research Funding - RTI Health Solutions (Inst)
 
Yu-Hsuan Shih
Employment - Janssen; Novartis
Stock and Other Ownership Interests - Novartis
 
Beilei Cai
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Julien Rombi
No Relationships to Disclose
 
Keith L. Davis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Celgene (Inst); Eisai (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst); SOBI (Inst)
 
Nydia Caro
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
 
Teddy Rassem Saliba
Employment - Novartis
Stock and Other Ownership Interests - Novartis